Product Details
| Product Name:
Incyclinide |
CAS No.:
15866-90-7 |
| Purity:
97.99% |
Supply Ability:
10g |
| Release date:
2025/10/20 |
Product Introduction
Bioactivity
| Name | Incyclinide |
| Description | Chemically modified tetracyclines (CMTs) can inhibit MMPs, but lack antimicrobial activity. Nonantimicrobial derivative of tetracycline called incyclinide (COL-3, CMT-3). Incyclinide (CMT-3) has been shown to experimentally suppress prostate cancer, colon adenocarcinoma and melanoma invasiveness in cell culture and to inhibit tumor growth and metastasis. |
| In vitro | Incyclinide has been shown to experimentally suppress prostate cancer, colon adenocarcinoma, and melanoma invasiveness in cell culture. Adding incyclinide at final concentrations of 5 to 20 μM inhibits MT1-MMP gelatinolytic and caseinolytic activity, blocks MT1-MMPactivation of pro-MMP-2, and decreases invasiveness of HT-1080 fibrosarcoma cells [1]. Most of the MICs of CMT-3 against filamentous fungi are found to be between 0.25 and 8 μg/mL, and the inhibition of viability of these fungi by incyclinide is routinely higher than 90% [2]. |
| In vivo | Probably by reducing the number of osteoclasts at the compression side, Incyclinide suppresses tooth movement in the rat. Reduced MMP activity by incyclinide might also directly inhibit degradation of the organic bone matrix. This might be due to the induction of apoptosis in activated osteoclasts or reduced osteoclast migration [3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 95 mg/mL (255.83 mM), Sonication is recommended.
|
| Keywords | MT1-MMP | MMP | Matrix metalloproteinases | Inhibitor | inhibit | Incyclinide | COL3 | COL 3 | CMT3 | CMT 3 |
| Inhibitors Related | Stigmasterol | Ethyl gallate | Doxycycline (hyclate) | Astragaloside IV | Doxycycline | Edaravone | Glucosamine | Bovine Type II Collagen | Triolein | Arctigenin | Fenofibric acid | Glucosamine sulfate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:62-33-9
$0.00 / 1removed
-
CAS:23313-21-5
$36.00 / 1mg
-
CAS:105650-23-5
$136.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States